Date published: 2025-9-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

OATP-J Inhibitors

OATP-J inhibitors are a class of chemical compounds designed to selectively inhibit the function of the organic anion-transporting polypeptide J (OATP-J), a member of the solute carrier organic anion transporter family. OATP-J is involved in the transmembrane transport of a wide variety of organic anions, including bile acids, hormones, and xenobiotics. OATP-J inhibitors act by binding to the transporter, thereby blocking the active site or preventing conformational changes necessary for substrate translocation. The inhibition of OATP-J can either be competitive, where the inhibitor directly competes with the substrate for the binding site, or non-competitive, where the inhibitor binds to an alternative site that indirectly impairs transporter function. The molecular design of these inhibitors often focuses on mimicking the structure of natural substrates to ensure effective interaction with the transporter while incorporating modifications that prevent their actual transport across the membrane.

The development of OATP-J inhibitors is guided by an in-depth understanding of the transporter's structure and binding characteristics. Structural studies using methods like cryo-electron microscopy (cryo-EM) and homology modeling provide detailed insights into the binding pocket and help identify key amino acid residues involved in substrate recognition. Computational approaches, such as molecular docking and quantitative structure-activity relationship (QSAR) modeling, are used to design and optimize inhibitors that exhibit high affinity and specificity for OATP-J. Chemical modifications, such as the introduction of bulky groups or altering the electronic properties of the core structure, are often employed to increase binding strength and specificity while preventing transport activity. OATP-J inhibitors can be diverse in chemical nature, including small organic molecules, peptidomimetics, or even macrocycles, depending on the mechanism of inhibition being targeted. Factors such as lipophilicity, stability, and membrane permeability are also carefully considered during the development process to ensure the effective interaction of these inhibitors with OATP-J in biological environments. The design and synthesis of OATP-J inhibitors require a thorough understanding of transporter mechanisms, structure-activity relationships (SAR), and the physiochemical properties that influence binding and efficacy.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Cyclosporin A

59865-13-3sc-3503
sc-3503-CW
sc-3503A
sc-3503B
sc-3503C
sc-3503D
100 mg
100 mg
500 mg
10 g
25 g
100 g
$62.00
$90.00
$299.00
$475.00
$1015.00
$2099.00
69
(5)

Cyclosporine A is known to inhibit several OATP family members, potentially affecting the transport activity of OATP-J.

Rifampicin

13292-46-1sc-200910
sc-200910A
sc-200910B
sc-200910C
1 g
5 g
100 g
250 g
$95.00
$322.00
$663.00
$1438.00
6
(1)

Rifampicin can act as an inhibitor of certain OATP transporters, potentially influencing OATP-J related transport processes.

Atorvastatin

134523-00-5sc-337542A
sc-337542
50 mg
100 mg
$252.00
$495.00
9
(1)

Atorvastatin, a commonly used statin, is known to interact with OATP transporters, which may include effects on OATP-J.

Erythromycin

114-07-8sc-204742
sc-204742A
sc-204742B
sc-204742C
5 g
25 g
100 g
1 kg
$56.00
$240.00
$815.00
$1305.00
4
(3)

Erythromycin, a macrolide antibiotic, has been reported to inhibit various OATP transporters, potentially affecting OATP-J.

Gemfibrozil

25812-30-0sc-204764
sc-204764A
5 g
25 g
$65.00
$262.00
2
(2)

Gemfibrozil, a lipid-regulating agent, can inhibit OATP transporter activity, possibly influencing OATP-J.

Indinavir

150378-17-9sc-353630
100 mg
$982.00
1
(0)

Indinavir, an antiretroviral drug, is known to interact with and inhibit certain OATP transporters, potentially affecting OATP-J.

Losartan

114798-26-4sc-353662
100 mg
$127.00
18
(1)

Losartan, an angiotensin II receptor antagonist, may influence OATP transporter activity, possibly affecting OATP-J.

Probenecid

57-66-9sc-202773
sc-202773A
sc-202773B
sc-202773C
1 g
5 g
25 g
100 g
$27.00
$38.00
$98.00
$272.00
28
(2)

Probenecid, a uricosuric drug, is known to inhibit various transporters, including some OATP family members, potentially affecting OATP-J.

Itraconazole

84625-61-6sc-205724
sc-205724A
50 mg
100 mg
$76.00
$139.00
23
(1)

Itraconazole, an antifungal agent, can inhibit OATP transporter activity, potentially influencing OATP-J.

Fexofenadine

83799-24-0sc-218475
100 mg
$292.00
1
(0)

Fexofenadine, an antihistamine, has been shown to interact with OATP transporters, possibly affecting OATP-J.